≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Generalized pustular psoriasis

DOID EFO Endpoint Browser PheWeb

L12_PSORI_PUSTGEN

impetigo herpetiformis: An impetigo that is characterized as a form of severe pustular psoriasis occurring in pregnancy.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — L40.1
  • Hospital discharge: ICD-9 — 6961B
  • Hospital discharge: ICD-8 — 69610
  • Cause of death: ICD-10 — L40.1
  • Cause of death: ICD-9 — 6961B
  • Cause of death: ICD-8 — 69610

2 out of 7 registries used, show all original rules.

136

4. Check minimum number of events

None

136

5. Include endpoints

None

136

6. Filter based on genotype QC (FinnGen only)

130

Control definitions (FinnGen only)

Control exclude
L12_PAPULOSQUAMOUS

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
L40
Name in latin
Psoriasis pustulosa generalisata

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 983 481 487
Only index persons 740 384 356
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 54.30 56.74 51.88
Only index persons 52.55 54.23 50.72

-FinnGen-

Key figures

All Female Male
Number of individuals 130 72 58
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 52.37 50.72 54.42

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
136
Matched controls
1360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
148.5
114
*
D05AX52
ATC
calcipotriol, combinations; topical
82.1
115.1
65
15
L40.0
ICD-10 Finland
Psoriasis vulgaris
439.8
85.0
77
*
D07XC01
ATC
betamethasone; topical
23.3
78.6
76
70
D05AX02
ATC
calcipotriol; topical
374.5
66.7
62
*
L04AX03
ATC
methotrexate; systemic
19.3
64.4
64
60
D05BB02
ATC
acitretin; oral
272.8
64.2
61
*
D07AD01
ATC
clobetasol; topical
13.3
52.7
73
109
L40.5
ICD-10 Finland
Arthropathic psoriasis
+∞
45.4
41
*
D07AC01
ATC
betamethasone; topical
15.2
44.7
113
333
E000003, ,
ATC
21.9
44.3
36
22
E000001, ,
ATC
10.3
42.8
75
145
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
+∞
41.9
38
*
E0000UV, ,
ATC
14.4
39.1
116
390
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
10.9
36.6
49
67
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
36.1
33
*
D05AX03
ATC
calcitriol; topical
435.1
34.5
33
*
L40.9
ICD-10 Finland
Psoriasis, unspecified
224.3
34.5
34
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
9.3
32.6
50
80
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.2
26.1
31
35
A07EC01
ATC
sulfasalazine; oral, rectal
9.1
25.1
36
52
D07AB02
ATC
hydrocortisone butyrate; topical
5.9
23.9
78
254
134
Kela drug reimbursment
General erythroderma
274.3
23.4
23
*
L40.8
ICD-10 Finland
Other psoriasis
260.1
22.3
22
*
D07AC13
ATC
mometasone; topical
5.5
22.2
76
254
L04AB04
ATC
adalimumab; parenteral
36.9
21.5
27
9
L01BA01
ATC
methotrexate; systemic
22.2
20.7
30
17
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
86.5
20.4
22
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
23.7
19.1
27
14
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
22.1
18.7
27
15
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.2
18.2
27
40
D07AB08
ATC
desonide; topical
6.0
17.9
39
86
L04AD01
ATC
ciclosporin; systemic
30.7
16.2
21
8
E000002, ,
ATC
5.8
15.7
34
74
TQW80
NOMESCO Finland
Local dermatologic skincare
21.6
15.3
22
12
L04AA01
ATC
[U] ciclosporin
64.2
15.2
17
*
M07.3
ICD-10 Finland
Other psoriatic arthropathies
+∞
13.8
13
*
L04AC10
ATC
secukinumab; parenteral
154.8
13.7
14
*
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
154.8
13.7
14
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.2
13.3
47
152
H02AB06
ATC
prednisolone; systemic
4.0
13.2
93
479
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
+∞
12.7
12
*
L04AB01
ATC
etanercept; parenteral
24.0
12.4
17
8
6961B
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS PUSTULARIS]
+∞
11.6
11
*
L04AC05
ATC
ustekinumab; parenteral
+∞
11.6
11
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
11.6
11
*
L40
ICD-10 Finland
Psoriasis
38.7
11.5
14
*
69610
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis pustulosa
+∞
10.5
10
*
D02AE01
ATC
carbamide; topical
5.5
9.9
21
44
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.5
9.8
27
71
L04AC13
ATC
ixekizumab; parenteral
107.2
9.5
10
*
D07BA04
ATC
hydrocortisone and antiseptics; topical
4.8
9.3
23
55
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
4.0
9.3
31
94
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
39.5
9.2
11
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.6
9.0
24
61
E000006, ,
ATC
5.5
8.6
18
37
H02AB07
ATC
prednisone; oral
3.8
8.6
31
99
L04AA13
ATC
[U] leflunomide
11.9
8.5
15
14
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
8.4
8
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
8.4
8
*
L04AA11
ATC
[U] etanercept
+∞
8.4
8
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
7.8
84
497
S91
ICPC
Psoriasis
47.8
7.8
9
*
D02AX
ATC
Other emollients and protectives
9.8
7.8
15
17
D05AA
ATC
Tars
+∞
7.4
7
*
L04AC21
ATC
bimekizumab; systemic
+∞
7.4
7
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.9
7.2
44
193
E000007, ,
ATC
6.3
7.1
18
32
D07AA02
ATC
hydrocortisone; topical
3.2
6.7
32
121
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.5
6.3
66
375

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.5e+00
3.4e+00
4.5e+00
1.0e+50
—
4.8e+00
3.2e+00
cases:37.50%
controls:4.80%
cases:37.50%
controls:1.89%
cases:27.34%
controls:0.39%
cases:75.78%
controls:0.00%
—
—
cases:76.98%
controls:2.57%
cases:60.53%
controls:5.93%
48
61
80
1210
48
24
80
1247
35
5
93
1266
97
0
31
1271
—
97
32
29
1214
69
67
45
1063
Outpatient Visit
OP [9202]
9.9e-01
1.2e+00
1.6e+00
5.7e+00
2.4e+00
1.9e+00
1.2e+00
cases:78.13%
controls:57.12%
cases:64.84%
controls:36.66%
cases:28.91%
controls:7.79%
cases:53.91%
controls:0.39%
cases:50.78%
controls:8.42%
cases:81.75%
controls:40.29%
cases:86.84%
controls:65.49%
100
726
28
545
83
466
45
805
37
99
91
1172
69
5
59
1266
65
107
63
1164
103
502
23
744
99
740
15
390
betamethasone
C05AA05 [21601610]
2.1e+00
3.2e+00
3.7e+00
1.0e+50
—
3.1e+00
2.4e+00
cases:32.81%
controls:5.82%
cases:32.03%
controls:1.81%
cases:14.06%
controls:0.39%
cases:3.91%
controls:0.00%
—
—
cases:35.71%
controls:2.33%
cases:42.11%
controls:5.93%
42
74
86
1197
41
23
87
1248
18
5
110
1266
5
0
123
1271
—
45
29
81
1217
48
67
66
1063
betamethasone
S02BA07 [21605169]
2.1e+00
3.2e+00
3.7e+00
1.0e+50
—
3.1e+00
2.4e+00
cases:32.81%
controls:5.82%
cases:32.03%
controls:1.81%
cases:14.06%
controls:0.39%
cases:3.91%
controls:0.00%
—
—
cases:35.71%
controls:2.33%
cases:42.11%
controls:5.93%
42
74
86
1197
41
23
87
1248
18
5
110
1266
5
0
123
1271
—
45
29
81
1217
48
67
66
1063
betamethasone
A07EA04 [21600656]
2.1e+00
3.2e+00
3.7e+00
1.0e+50
—
3.1e+00
2.4e+00
cases:32.81%
controls:5.82%
cases:32.03%
controls:1.81%
cases:14.06%
controls:0.39%
cases:3.91%
controls:0.00%
—
—
cases:35.71%
controls:2.33%
cases:42.11%
controls:5.93%
42
74
86
1197
41
23
87
1248
18
5
110
1266
5
0
123
1271
—
45
29
81
1217
48
67
66
1063
betamethasone
D07AC01 [21602120]
2.1e+00
3.2e+00
3.7e+00
1.0e+50
—
3.1e+00
2.4e+00
cases:32.81%
controls:5.82%
cases:32.03%
controls:1.81%
cases:14.06%
controls:0.39%
cases:3.91%
controls:0.00%
—
—
cases:35.71%
controls:2.33%
cases:42.11%
controls:5.93%
42
74
86
1197
41
23
87
1248
18
5
110
1266
5
0
123
1271
—
45
29
81
1217
48
67
66
1063
combinations of corticosteroids
D07XB30 [21602188]
2.2e+00
2.9e+00
3.5e+00
1.0e+50
—
3.1e+00
2.4e+00
cases:47.66%
controls:9.28%
cases:37.50%
controls:3.15%
cases:15.63%
controls:0.55%
cases:4.69%
controls:0.00%
—
—
cases:41.27%
controls:3.21%
cases:52.63%
controls:9.03%
61
118
67
1153
48
40
80
1231
20
7
108
1264
6
0
122
1271
—
52
40
74
1206
60
102
54
1028
combinations of corticosteroids
D07AB30 [21602118]
2.2e+00
2.9e+00
3.5e+00
1.0e+50
—
3.1e+00
2.4e+00
cases:47.66%
controls:9.28%
cases:37.50%
controls:3.15%
cases:15.63%
controls:0.55%
cases:4.69%
controls:0.00%
—
—
cases:41.27%
controls:3.21%
cases:52.63%
controls:9.03%
61
118
67
1153
48
40
80
1231
20
7
108
1264
6
0
122
1271
—
52
40
74
1206
60
102
54
1028
clobetasol
D07AD01 [21602141]
2.8e+00
3.9e+00
1.0e+50
1.0e+50
—
4.1e+00
2.7e+00
cases:21.09%
controls:1.65%
cases:18.75%
controls:0.47%
cases:9.38%
controls:0.00%
cases:4.69%
controls:0.00%
—
—
cases:25.40%
controls:0.56%
cases:27.19%
controls:2.39%
27
21
101
1250
24
6
104
1265
12
0
116
1271
6
0
122
1271
—
32
7
94
1239
31
27
83
1103
methotrexate; oral, parenteral
L04AX03 [21603929]
3.4e+00
3.0e+00
—
—
—
3.4e+00
3.2e+00
cases:23.44%
controls:1.02%
cases:15.63%
controls:0.94%
—
—
—
—
—
—
cases:22.22%
controls:0.96%
cases:28.95%
controls:1.59%
30
13
98
1258
20
12
108
1259
—
—
—
28
12
98
1234
33
18
81
1112
methotrexate
L01BA01 [21601423]
3.4e+00
3.0e+00
—
—
—
3.4e+00
3.2e+00
cases:23.44%
controls:1.02%
cases:15.63%
controls:0.94%
—
—
—
—
—
—
cases:22.22%
controls:0.96%
cases:28.95%
controls:1.59%
30
13
98
1258
20
12
108
1259
—
—
—
28
12
98
1234
33
18
81
1112
Rheumatology
66 [38004491]
2.5e+00
3.6e+00
—
1.0e+50
—
3.2e+00
2.5e+00
cases:18.75%
controls:1.89%
cases:16.41%
controls:0.55%
—
—
cases:5.47%
controls:0.00%
—
—
cases:22.22%
controls:1.12%
cases:27.19%
controls:3.01%
24
24
104
1247
21
7
107
1264
—
7
0
121
1271
—
28
14
98
1232
31
34
83
1096
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.1e+00
1.7e+00
2.5e+00
—
3.0e+00
2.1e+00
1.2e+00
cases:10.94%
controls:4.01%
cases:13.28%
controls:2.75%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.47%
cases:16.67%
controls:2.33%
cases:22.81%
controls:8.05%
14
51
114
1220
17
35
111
1236
7
6
121
1265
—
11
6
117
1265
21
29
105
1217
26
91
88
1039
Basophils [#/volume] in Blood
26444-0 [3006315]
1.1e+00
1.7e+00
2.5e+00
—
3.0e+00
2.1e+00
1.2e+00
cases:10.94%
controls:4.01%
cases:13.28%
controls:2.75%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.47%
cases:16.67%
controls:2.33%
cases:22.81%
controls:8.23%
14
51
114
1220
17
35
111
1236
7
6
121
1265
—
11
6
117
1265
21
29
105
1217
26
93
88
1037
other preparations, combinations; ointment
C05AX03 [21601631]
2.5e+00
3.0e+00
—
—
—
3.2e+00
2.8e+00
cases:19.53%
controls:1.89%
cases:12.50%
controls:0.71%
—
—
—
—
—
—
cases:17.46%
controls:0.88%
cases:21.93%
controls:1.59%
25
24
103
1247
16
9
112
1262
—
—
—
22
11
104
1235
25
18
89
1112
betamethasone
S03BA03 [21605203]
2.3e+00
2.9e+00
—
—
1.0e+50
3.2e+00
2.7e+00
cases:19.53%
controls:2.36%
cases:13.28%
controls:0.87%
—
—
—
—
cases:4.69%
controls:0.00%
cases:18.25%
controls:0.88%
cases:23.68%
controls:2.04%
25
30
103
1241
17
11
111
1260
—
—
6
0
122
1271
23
11
103
1235
27
23
87
1107
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.1e+00
1.7e+00
2.5e+00
—
3.2e+00
2.2e+00
1.3e+00
cases:10.16%
controls:3.62%
cases:11.72%
controls:2.28%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.39%
cases:15.08%
controls:1.93%
cases:21.93%
controls:7.08%
13
46
115
1225
15
29
113
1242
7
6
121
1265
—
11
5
117
1266
19
24
107
1222
25
80
89
1050
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.1e+00
1.7e+00
2.5e+00
—
3.2e+00
2.2e+00
1.3e+00
cases:10.16%
controls:3.62%
cases:11.72%
controls:2.28%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.39%
cases:15.08%
controls:1.93%
cases:21.93%
controls:7.17%
13
46
115
1225
15
29
113
1242
7
6
121
1265
—
11
5
117
1266
19
24
107
1222
25
81
89
1049
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.1e+00
1.7e+00
2.5e+00
—
3.2e+00
2.2e+00
1.3e+00
cases:10.16%
controls:3.62%
cases:11.72%
controls:2.36%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.39%
cases:15.08%
controls:2.01%
cases:21.93%
controls:7.08%
13
46
115
1225
15
30
113
1241
7
6
121
1265
—
11
5
117
1266
19
25
107
1221
25
80
89
1050
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.0e+00
1.7e+00
2.5e+00
—
3.2e+00
2.1e+00
1.2e+00
cases:9.38%
controls:3.54%
cases:11.72%
controls:2.44%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.39%
cases:15.08%
controls:2.09%
cases:21.93%
controls:7.70%
12
45
116
1226
15
31
113
1240
7
6
121
1265
—
11
5
117
1266
19
26
107
1220
25
87
89
1043
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.1e+00
1.7e+00
2.5e+00
—
3.2e+00
2.1e+00
1.2e+00
cases:10.16%
controls:3.70%
cases:11.72%
controls:2.36%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.39%
cases:14.29%
controls:2.09%
cases:21.93%
controls:7.79%
13
47
115
1224
15
30
113
1241
7
6
121
1265
—
11
5
117
1266
18
26
108
1220
25
88
89
1042
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.0e+00
1.7e+00
2.5e+00
—
3.0e+00
2.1e+00
1.2e+00
cases:10.94%
controls:4.17%
cases:13.28%
controls:2.83%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.47%
cases:16.67%
controls:2.33%
cases:23.68%
controls:8.58%
14
53
114
1218
17
36
111
1235
7
6
121
1265
—
11
6
117
1265
21
29
105
1217
27
97
87
1033
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
2.1e+00
2.8e+00
—
—
1.0e+50
2.9e+00
2.6e+00
cases:21.88%
controls:3.23%
cases:14.84%
controls:1.02%
—
—
—
—
cases:3.91%
controls:0.00%
cases:20.63%
controls:1.36%
cases:28.95%
controls:3.01%
28
41
100
1230
19
13
109
1258
—
—
5
0
123
1271
26
17
100
1229
33
34
81
1096
prednisolone; oral, parenteral
H02AB06 [21602734]
8.7e-01
1.6e+00
1.8e+00
—
2.7e+00
2.0e+00
1.4e+00
cases:17.97%
controls:8.42%
cases:17.19%
controls:3.93%
cases:7.03%
controls:1.18%
—
—
cases:7.81%
controls:0.55%
cases:24.60%
controls:4.25%
cases:30.70%
controls:10.09%
23
107
105
1164
22
50
106
1221
9
15
119
1256
—
10
7
118
1264
31
53
95
1193
35
114
79
1016
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.1e+00
1.7e+00
2.5e+00
—
3.0e+00
2.1e+00
1.2e+00
cases:10.94%
controls:4.09%
cases:13.28%
controls:2.75%
cases:5.47%
controls:0.47%
—
—
cases:8.59%
controls:0.47%
cases:16.67%
controls:2.41%
cases:23.68%
controls:8.85%
14
52
114
1219
17
35
111
1236
7
6
121
1265
—
11
6
117
1265
21
30
105
1216
27
100
87
1030
prednisolone
A07EA01 [21600653]
8.7e-01
1.6e+00
1.8e+00
—
2.7e+00
2.0e+00
1.4e+00
cases:17.97%
controls:8.42%
cases:17.19%
controls:4.01%
cases:7.03%
controls:1.18%
—
—
cases:7.81%
controls:0.55%
cases:24.60%
controls:4.25%
cases:30.70%
controls:10.18%
23
107
105
1164
22
51
106
1220
9
15
119
1256
—
10
7
118
1264
31
53
95
1193
35
115
79
1015
mometasone
D07AC13 [21602132]
1.8e+00
2.5e+00
—
—
—
2.5e+00
2.2e+00
cases:16.41%
controls:3.23%
cases:13.28%
controls:1.26%
—
—
—
—
—
—
cases:12.70%
controls:1.20%
cases:28.07%
controls:4.34%
21
41
107
1230
17
16
111
1255
—
—
—
16
15
110
1231
32
49
82
1081
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.7e-01
1.3e+00
2.1e+00
—
2.3e+00
1.8e+00
1.1e+00
cases:10.94%
controls:4.88%
cases:12.50%
controls:3.62%
cases:6.25%
controls:0.79%
—
—
cases:8.59%
controls:0.94%
cases:16.67%
controls:3.21%
cases:23.68%
controls:9.03%
14
62
114
1209
16
46
112
1225
8
10
120
1261
—
11
12
117
1259
21
40
105
1206
27
102
87
1028
cefalexin; oral
J01DB01 [21602870]
7.0e-01
1.4e+00
2.1e+00
—
2.6e+00
9.0e-01
7.8e-01
cases:40.63%
controls:25.33%
cases:25.78%
controls:7.71%
cases:11.72%
controls:1.57%
—
—
cases:9.38%
controls:0.79%
cases:16.67%
controls:7.54%
cases:45.61%
controls:27.70%
52
322
76
949
33
98
95
1173
15
20
113
1251
—
12
10
116
1261
21
94
105
1152
52
313
62
817
hydrocortisone buteprate
D07AB11 [21602115]
1.8e+00
2.4e+00
—
—
1.0e+50
2.4e+00
1.4e+00
cases:24.22%
controls:5.04%
cases:14.84%
controls:1.57%
—
—
—
—
cases:8.59%
controls:0.00%
cases:19.05%
controls:2.01%
cases:21.93%
controls:6.46%
31
64
97
1207
19
20
109
1251
—
—
11
0
117
1271
24
25
102
1221
25
73
89
1057
hydrocortisone aceponate
D07AC16 [21602135]
1.8e+00
2.4e+00
—
—
1.0e+50
2.4e+00
1.4e+00
cases:24.22%
controls:5.04%
cases:14.84%
controls:1.57%
—
—
—
—
cases:8.59%
controls:0.00%
cases:19.05%
controls:2.01%
cases:21.93%
controls:6.46%
31
64
97
1207
19
20
109
1251
—
—
11
0
117
1271
24
25
102
1221
25
73
89
1057
hydrocortisone butyrate
D07AB02 [21602106]
1.8e+00
2.4e+00
—
—
1.0e+50
2.4e+00
1.4e+00
cases:24.22%
controls:5.04%
cases:14.84%
controls:1.57%
—
—
—
—
cases:8.59%
controls:0.00%
cases:19.05%
controls:2.01%
cases:21.93%
controls:6.46%
31
64
97
1207
19
20
109
1251
—
—
11
0
117
1271
24
25
102
1221
25
73
89
1057
hydrocortisone
D07AA02 [21602102]
1.8e+00
2.4e+00
—
—
1.0e+50
2.4e+00
1.4e+00
cases:24.22%
controls:5.04%
cases:14.84%
controls:1.57%
—
—
—
—
cases:8.59%
controls:0.00%
cases:19.05%
controls:2.01%
cases:21.93%
controls:6.46%
31
64
97
1207
19
20
109
1251
—
—
11
0
117
1271
24
25
102
1221
25
73
89
1057
hydrocortisone
C05AA01 [21601608]
1.7e+00
2.4e+00
—
—
1.0e+50
2.4e+00
1.4e+00
cases:24.22%
controls:5.27%
cases:14.84%
controls:1.57%
—
—
—
—
cases:8.59%
controls:0.00%
cases:19.05%
controls:2.01%
cases:21.93%
controls:6.46%
31
67
97
1204
19
20
109
1251
—
—
11
0
117
1271
24
25
102
1221
25
73
89
1057
hydrocortisone
A07EA02 [21600654]
1.7e+00
2.4e+00
—
—
1.0e+50
2.4e+00
1.4e+00
cases:24.22%
controls:5.27%
cases:14.84%
controls:1.57%
—
—
—
—
cases:8.59%
controls:0.00%
cases:19.05%
controls:2.01%
cases:21.93%
controls:6.46%
31
67
97
1204
19
20
109
1251
—
—
11
0
117
1271
24
25
102
1221
25
73
89
1057
hydrocortisone
S02BA01 [21605166]
1.6e+00
2.3e+00
—
—
1.0e+50
2.4e+00
1.5e+00
cases:18.75%
controls:4.48%
cases:11.72%
controls:1.26%
—
—
—
—
cases:7.03%
controls:0.00%
cases:15.87%
controls:1.61%
cases:20.18%
controls:5.40%
24
57
104
1214
15
16
113
1255
—
—
9
0
119
1271
20
20
106
1226
23
61
91
1069
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.4e+00
1.7e+00
2.3e+00
—
—
2.4e+00
1.6e+00
cases:10.16%
controls:2.75%
cases:9.38%
controls:1.81%
cases:3.91%
controls:0.39%
—
—
—
—
cases:12.70%
controls:1.28%
cases:16.67%
controls:3.89%
13
35
115
1236
12
23
116
1248
5
5
123
1266
—
—
16
16
110
1230
19
44
95
1086
Dermatitis, unspecified
L30.9 [45572271]
1.7e+00
2.6e+00
—
1.0e+50
1.0e+50
2.1e+00
1.0e+00
cases:6.25%
controls:1.18%
cases:7.81%
controls:0.63%
—
—
cases:3.91%
controls:0.00%
cases:3.91%
controls:0.00%
cases:5.56%
controls:0.72%
cases:4.39%
controls:1.59%
8
15
120
1256
10
8
118
1263
—
5
0
123
1271
5
0
123
1271
7
9
119
1237
5
18
109
1112
Pharmacy visit
OMOP4822462 [581458]
3.2e-02
9.0e-01
1.2e+00
2.5e+00
1.5e+00
1.1e+00
7.3e-01
cases:84.38%
controls:83.95%
cases:88.28%
controls:75.37%
cases:67.97%
controls:39.73%
cases:20.31%
controls:2.12%
cases:75.78%
controls:40.20%
cases:91.27%
controls:77.13%
cases:94.74%
controls:89.65%
108
1067
20
204
113
958
15
313
87
505
41
766
26
27
102
1244
97
511
31
760
115
961
11
285
108
1013
6
117
desonide
D07AB08 [21602112]
1.9e+00
2.0e+00
1.0e+50
—
1.0e+50
—
2.2e+00
cases:7.03%
controls:1.10%
cases:4.69%
controls:0.63%
cases:3.91%
controls:0.00%
—
—
cases:7.03%
controls:0.00%
—
—
cases:12.28%
controls:1.59%
9
14
119
1257
6
8
122
1263
5
0
123
1271
—
9
0
119
1271
—
14
18
100
1112
Inpatient Hospital
21 [8717]
7.6e-01
7.6e-01
2.0e+00
1.0e+50
2.2e+00
1.1e+00
6.0e-01
cases:48.44%
controls:30.53%
cases:19.53%
controls:10.15%
cases:10.94%
controls:1.57%
cases:20.31%
controls:0.00%
cases:14.06%
controls:1.73%
cases:24.60%
controls:10.11%
cases:39.47%
controls:26.28%
62
388
66
883
25
129
103
1142
14
20
114
1251
26
0
102
1271
18
22
110
1249
31
126
95
1120
45
297
69
833
prednisone; oral
H02AB07 [21602735]
2.1e+00
—
—
—
—
2.0e+00
1.9e+00
cases:7.03%
controls:0.94%
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.64%
cases:6.14%
controls:0.97%
9
12
119
1259
—
—
—
—
6
8
120
1238
7
11
107
1119
prednisone
A07EA03 [21600655]
2.1e+00
—
—
—
—
2.0e+00
1.9e+00
cases:7.03%
controls:0.94%
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.64%
cases:6.14%
controls:0.97%
9
12
119
1259
—
—
—
—
6
8
120
1238
7
11
107
1119
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.3e-01
8.5e-01
1.7e+00
—
2.2e+00
1.1e+00
3.9e-01
cases:14.84%
controls:11.17%
cases:17.97%
controls:8.58%
cases:7.81%
controls:1.57%
—
—
cases:10.16%
controls:1.18%
cases:19.05%
controls:7.38%
cases:30.70%
controls:23.10%
19
142
109
1129
23
109
105
1162
10
20
118
1251
—
13
15
115
1256
24
92
102
1154
35
261
79
869
antibiotics in combination with corticosteroids
D01AA20 [21601918]
1.4e+00
—
—
—
—
2.3e+00
2.9e+00
cases:4.69%
controls:1.18%
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.48%
cases:10.53%
controls:0.62%
6
15
122
1256
—
—
—
—
6
6
120
1240
12
7
102
1123
chlorhexidine
S02AA09 [21605155]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
hydrocortisone
D07XA01 [21602180]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
chlorhexidine
S03AA04 [21605193]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
chlorhexidine, combinations
D08AC52 [21602208]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
chlorhexidine
D09AA12 [21602275]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
hydrocortisone and antiseptics
D07BA04 [21602146]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.50%
6
18
122
1253
—
—
—
—
12
8
114
1238
13
17
101
1113
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.3e-01
1.4e+00
—
—
2.2e+00
1.3e+00
7.0e-01
cases:11.72%
controls:7.24%
cases:14.06%
controls:3.86%
—
—
—
—
cases:4.69%
controls:0.55%
cases:12.70%
controls:3.85%
cases:22.81%
controls:12.74%
15
92
113
1179
18
49
110
1222
—
—
6
7
122
1264
16
48
110
1198
26
144
88
986
triamcinolone and antiseptics
D07BB03 [21602150]
1.2e+00
—
—
—
—
2.8e+00
2.1e+00
cases:4.69%
controls:1.49%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.64%
cases:11.40%
controls:1.59%
6
19
122
1252
—
—
—
—
12
8
114
1238
13
18
101
1112
sulfasalazine; oral, rectal
A07EC01 [21600663]
2.5e+00
2.1e+00
—
—
—
2.0e+00
1.6e+00
cases:10.94%
controls:1.02%
cases:5.47%
controls:0.71%
—
—
—
—
—
—
cases:3.97%
controls:0.56%
cases:5.26%
controls:1.06%
14
13
114
1258
7
9
121
1262
—
—
—
5
7
121
1239
6
12
108
1118
Internal Medicine
11 [38004456]
4.6e-01
8.8e-01
1.7e+00
1.0e+50
1.2e+00
1.2e+00
7.2e-01
cases:28.91%
controls:20.38%
cases:20.31%
controls:9.60%
cases:7.03%
controls:1.34%
cases:10.16%
controls:0.00%
cases:6.25%
controls:2.05%
cases:23.81%
controls:8.43%
cases:34.21%
controls:20.27%
37
259
91
1012
26
122
102
1149
9
17
119
1254
13
0
115
1271
8
26
120
1245
30
105
96
1141
39
229
75
901
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.9e-01
9.0e-01
1.6e+00
—
2.0e+00
1.6e+00
8.5e-01
cases:13.28%
controls:7.16%
cases:12.50%
controls:5.51%
cases:4.69%
controls:0.94%
—
—
cases:7.81%
controls:1.10%
cases:17.46%
controls:4.01%
cases:28.07%
controls:14.34%
17
91
111
1180
16
70
112
1201
6
12
122
1259
—
10
14
118
1257
22
50
104
1196
32
162
82
968
Intravenous
ZX120 [2001311495]
—
—
—
—
—
2.3e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.48%
cases:7.02%
controls:0.97%
—
—
—
—
—
6
6
120
1240
8
11
106
1119
Normoblasts [#/volume] in Blood
715-3 [3021589]
8.1e-01
7.9e-01
1.9e+00
—
1.8e+00
1.2e+00
1.2e+00
cases:8.59%
controls:4.01%
cases:8.59%
controls:4.09%
cases:3.91%
controls:0.63%
—
—
cases:5.47%
controls:0.94%
cases:10.32%
controls:3.45%
cases:18.42%
controls:6.46%
11
51
117
1220
11
52
117
1219
5
8
123
1263
—
7
12
121
1259
13
43
113
1203
21
73
93
1057
Laceration/cut
S18 [2002000983]
1.1e+00
2.0e+00
—
—
—
2.1e+00
2.8e-01
cases:9.38%
controls:3.38%
cases:6.25%
controls:0.87%
—
—
—
—
—
—
cases:7.14%
controls:0.96%
cases:7.02%
controls:5.40%
12
43
116
1228
8
11
120
1260
—
—
—
9
12
117
1234
8
61
106
1069
hydrocortisone; oral, parenteral
H02AB09 [21602737]
—
—
—
—
—
2.1e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:6.35%
controls:0.80%
cases:8.77%
controls:1.33%
—
—
—
—
—
8
10
118
1236
10
15
104
1115
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.2e-01
7.1e-01
—
—
2.2e+00
1.5e+00
7.7e-01
cases:8.59%
controls:7.71%
cases:7.81%
controls:4.01%
—
—
—
—
cases:4.69%
controls:0.55%
cases:12.70%
controls:3.13%
cases:20.18%
controls:10.44%
11
98
117
1173
10
51
118
1220
—
—
6
7
122
1264
16
39
110
1207
23
118
91
1012
Case Management Agency
251B00000X [38004193]
4.9e-01
4.1e-01
5.3e-01
2.8e+00
8.1e-01
4.2e-01
6.2e-01
cases:51.56%
controls:39.42%
cases:42.97%
controls:33.36%
cases:21.09%
controls:13.61%
cases:13.28%
controls:0.94%
cases:26.56%
controls:13.85%
cases:45.24%
controls:35.15%
cases:73.68%
controls:60.09%
66
501
62
770
55
424
73
847
27
173
101
1098
17
12
111
1259
34
176
94
1095
57
438
69
808
84
679
30
451
cetirizine; oral
R06AE07 [21603497]
3.2e-01
9.6e-01
2.3e+00
—
-1.0e+50
7.4e-01
1.0e+00
cases:9.38%
controls:7.00%
cases:7.81%
controls:3.15%
cases:4.69%
controls:0.47%
—
—
cases:0.00%
controls:0.39%
cases:7.14%
controls:3.53%
cases:15.79%
controls:6.19%
12
89
116
1182
10
40
118
1231
6
6
122
1265
—
0
5
128
1266
9
44
117
1202
18
70
96
1060
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
—
3.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:0.44%
—
—
—
—
—
—
12
5
102
1125
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
—
—
—
—
—
1.0e+50
3.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.00%
cases:9.65%
controls:0.44%
—
—
—
—
—
6
0
120
1246
11
5
103
1125
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
3.0e+00
1.0e+50
—
1.0e+50
—
—
—
cases:8.59%
controls:0.47%
cases:3.91%
controls:0.00%
—
—
cases:10.94%
controls:0.00%
—
—
—
—
—
—
11
6
117
1265
5
0
123
1271
—
14
0
114
1271
—
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.2e-01
6.1e-01
1.4e+00
—
1.9e+00
1.1e+00
3.1e-01
cases:16.41%
controls:12.43%
cases:16.41%
controls:9.68%
cases:7.03%
controls:1.89%
—
—
cases:12.50%
controls:2.12%
cases:22.22%
controls:8.91%
cases:33.33%
controls:26.90%
21
158
107
1113
21
123
107
1148
9
24
119
1247
—
16
27
112
1244
28
111
98
1135
38
304
76
826
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
2.9e+00
—
—
—
—
—
—
cases:9.38%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
12
7
116
1264
—
—
—
—
—
—
antibiotics in combination with other drugs
S01AA20 [21603571]
8.1e-01
1.2e+00
—
—
—
1.7e+00
1.0e+00
cases:8.59%
controls:4.01%
cases:3.91%
controls:1.18%
—
—
—
—
—
—
cases:6.35%
controls:1.20%
cases:16.67%
controls:6.55%
11
51
117
1220
5
15
123
1256
—
—
—
8
15
118
1231
19
74
95
1056
Medical doctor
Z2221 [2001311556]
6.9e-01
1.1e+00
—
1.0e+50
—
1.5e+00
1.2e+00
cases:6.25%
controls:3.23%
cases:5.47%
controls:1.89%
—
—
cases:4.69%
controls:0.00%
—
—
cases:7.94%
controls:1.85%
cases:12.28%
controls:3.89%
8
41
120
1230
7
24
121
1247
—
6
0
122
1271
—
10
23
116
1223
14
44
100
1086
calcium (different salts in combination); oral
A12AA20 [21600872]
6.3e-01
6.1e-01
—
—
1.5e+00
1.4e+00
1.4e+00
cases:10.16%
controls:5.66%
cases:7.81%
controls:4.41%
—
—
—
—
cases:3.91%
controls:0.87%
cases:16.67%
controls:4.90%
cases:27.19%
controls:8.41%
13
72
115
1199
10
56
118
1215
—
—
5
11
123
1260
21
61
105
1185
31
95
83
1035
hydrocortisone and antiinfectives
S02CA03 [21605175]
1.5e+00
—
—
—
—
—
2.5e+00
cases:4.69%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:0.80%
6
14
122
1257
—
—
—
—
—
10
9
104
1121
hydrocortisone and antiinfectives
S03CA04 [21605208]
1.5e+00
—
—
—
—
—
2.5e+00
cases:4.69%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:0.80%
6
14
122
1257
—
—
—
—
—
10
9
104
1121
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
7.1e-01
1.6e+00
—
—
—
2.5e+00
—
cases:3.91%
controls:1.97%
cases:5.47%
controls:1.10%
—
—
—
—
—
—
cases:7.94%
controls:0.72%
—
—
5
25
123
1246
7
14
121
1257
—
—
—
10
9
116
1237
—
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
-1.0e+50
—
—
—
—
—
2.3e+00
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:0.53%
0
8
128
1263
—
—
—
—
—
6
6
108
1124
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
5.5e-01
9.8e-01
—
—
2.3e+00
8.9e-01
6.3e-01
cases:6.25%
controls:3.70%
cases:5.47%
controls:2.12%
—
—
—
—
cases:4.69%
controls:0.47%
cases:4.76%
controls:2.01%
cases:9.65%
controls:5.40%
8
47
120
1224
7
27
121
1244
—
—
6
6
122
1265
6
25
120
1221
11
61
103
1069
folic acid
V04CX02 [715877]
—
—
—
—
—
2.3e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.48%
cases:5.26%
controls:0.88%
—
—
—
—
—
6
6
120
1240
6
10
108
1120
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
—
—
—
2.3e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.48%
cases:5.26%
controls:0.88%
—
—
—
—
—
6
6
120
1240
6
10
108
1120
Supplier / Service Provider
OMOP5117446 [33004]
-1.3e+00
-7.4e-01
-1.0e+50
—
—
—
3.6e+00
cases:8.59%
controls:26.04%
cases:3.91%
controls:7.87%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:19.30%
controls:0.62%
11
331
117
940
5
100
123
1171
0
10
128
1261
—
—
—
22
7
92
1123
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
3.6e-01
4.2e-01
-1.0e+50
—
2.2e+00
5.5e-01
3.5e-01
cases:14.06%
controls:10.23%
cases:9.38%
controls:6.37%
cases:0.00%
controls:1.18%
—
—
cases:6.25%
controls:0.71%
cases:11.11%
controls:6.74%
cases:30.70%
controls:23.81%
18
130
110
1141
12
81
116
1190
0
15
128
1256
—
8
9
120
1262
14
84
112
1162
35
269
79
861
hydrocortisone; local oral
A01AC03 [21600036]
—
—
—
—
—
2.2e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.56%
cases:6.14%
controls:1.15%
—
—
—
—
—
6
7
120
1239
7
13
107
1117
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.7e-01
7.8e-01
1.1e+00
—
1.2e+00
1.2e+00
9.2e-01
cases:20.31%
controls:12.59%
cases:13.28%
controls:6.53%
cases:4.69%
controls:1.65%
—
—
cases:3.91%
controls:1.26%
cases:19.05%
controls:6.58%
cases:29.82%
controls:14.42%
26
160
102
1111
17
83
111
1188
6
21
122
1250
—
5
16
123
1255
24
82
102
1164
34
163
80
967
Hip X-ray examination
NF1AA [2001307894]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:0.71%
—
—
—
—
—
—
6
8
108
1122
alendronic acid; oral
M05BA04 [21604152]
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.64%
—
—
—
—
—
—
—
6
8
120
1238
—
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.7e-01
4.4e-01
-1.0e+50
—
2.0e+00
4.5e-01
2.5e-01
cases:14.06%
controls:11.09%
cases:10.94%
controls:7.32%
cases:0.00%
controls:1.26%
—
—
cases:5.47%
controls:0.79%
cases:11.11%
controls:7.38%
cases:30.70%
controls:25.66%
18
141
110
1130
14
93
114
1178
0
16
128
1255
—
7
10
121
1261
14
92
112
1154
35
290
79
840
Chronic apical periodontitis
K04.5 [45586691]
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.80%
—
—
—
—
—
—
—
7
10
119
1236
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
9.5e-01
4.9e-01
—
—
—
7.1e-01
1.0e+00
cases:14.84%
controls:6.29%
cases:3.91%
controls:2.44%
—
—
—
—
—
—
cases:4.76%
controls:2.41%
cases:14.91%
controls:6.02%
19
80
109
1191
5
31
123
1240
—
—
—
6
30
120
1216
17
68
97
1062
Emergency Room Visit
ER [9203]
5.6e-01
4.9e-01
2.0e+00
—
7.5e-01
8.0e-01
3.5e-01
cases:39.84%
controls:27.54%
cases:16.41%
controls:10.70%
cases:10.16%
controls:1.57%
—
—
cases:3.91%
controls:1.89%
cases:19.84%
controls:10.03%
cases:35.09%
controls:27.52%
51
350
77
921
21
136
107
1135
13
20
115
1251
—
5
24
123
1247
25
125
101
1121
40
311
74
819
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
9.8e-01
—
—
—
1.9e+00
2.2e-01
—
—
cases:3.91%
controls:1.49%
—
—
—
—
—
—
cases:6.35%
controls:0.96%
cases:4.39%
controls:3.54%
—
5
19
123
1252
—
—
—
8
12
118
1234
5
40
109
1090
pH of Urine
2756-5 [3015736]
2.5e-01
1.1e+00
—
—
—
1.9e+00
3.5e-01
cases:4.69%
controls:3.70%
cases:5.47%
controls:1.97%
—
—
—
—
—
—
cases:8.73%
controls:1.36%
cases:8.77%
controls:6.37%
6
47
122
1224
7
25
121
1246
—
—
—
11
17
115
1229
10
72
104
1058
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.9e+00
—
—
—
—
—
—
cases:5.47%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
121
1260
—
—
—
—
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.7e-01
8.4e-01
—
—
—
1.8e+00
1.5e-01
cases:5.47%
controls:4.64%
cases:7.03%
controls:3.15%
—
—
—
—
—
—
cases:11.90%
controls:2.25%
cases:9.65%
controls:8.41%
7
59
121
1212
9
40
119
1231
—
—
—
15
28
111
1218
11
95
103
1035
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.2e-01
2.1e-01
4.5e-01
—
1.7e+00
5.4e-01
3.8e-01
cases:14.84%
controls:12.27%
cases:11.72%
controls:9.76%
cases:3.91%
controls:2.52%
—
—
cases:10.16%
controls:1.97%
cases:15.08%
controls:9.39%
cases:32.46%
controls:24.78%
19
156
109
1115
15
124
113
1147
5
32
123
1239
—
13
25
115
1246
19
117
107
1129
37
280
77
850
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.3e-01
2.0e-01
4.5e-01
—
1.7e+00
5.0e-01
3.9e-01
cases:14.84%
controls:12.12%
cases:11.72%
controls:9.83%
cases:3.91%
controls:2.52%
—
—
cases:10.16%
controls:1.97%
cases:14.29%
controls:9.15%
cases:32.46%
controls:24.51%
19
154
109
1117
15
125
113
1146
5
32
123
1239
—
13
25
115
1246
18
114
108
1132
37
277
77
853
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.7e-01
1.6e-01
1.0e+00
—
1.7e+00
7.7e-01
6.5e-01
cases:11.72%
controls:10.07%
cases:9.38%
controls:8.10%
cases:4.69%
controls:1.73%
—
—
cases:9.38%
controls:1.81%
cases:15.08%
controls:7.62%
cases:27.19%
controls:16.28%
15
128
113
1143
12
103
116
1168
6
22
122
1249
—
12
23
116
1248
19
95
107
1151
31
184
83
946
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.1e-01
8.7e-01
—
—
—
1.7e+00
2.5e-01
cases:5.47%
controls:4.48%
cases:7.03%
controls:3.07%
—
—
—
—
—
—
cases:11.11%
controls:2.25%
cases:10.53%
controls:8.41%
7
57
121
1214
9
39
119
1232
—
—
—
14
28
112
1218
12
95
102
1035
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.6e-01
4.9e-01
8.3e-01
—
1.7e+00
7.8e-01
3.5e-01
cases:16.41%
controls:13.14%
cases:17.19%
controls:11.25%
cases:6.25%
controls:2.83%
—
—
cases:12.50%
controls:2.60%
cases:21.43%
controls:11.08%
cases:35.09%
controls:27.52%
21
167
107
1104
22
143
106
1128
8
36
120
1235
—
16
33
112
1238
27
138
99
1108
40
311
74
819
fluticasone; inhalant
R03BA05 [21603288]
9.4e-01
—
—
—
—
—
1.7e+00
cases:5.47%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
cases:7.02%
controls:1.42%
7
28
121
1243
—
—
—
—
—
8
16
106
1114
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
6.0e-01
—
—
—
—
1.7e+00
8.5e-01
cases:6.25%
controls:3.54%
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.44%
cases:11.40%
controls:5.22%
8
45
120
1226
—
—
—
—
9
18
117
1228
13
59
101
1071
General anesthesia, balanced
WX408 [2001310808]
1.7e+00
-1.0e+50
—
—
—
—
—
cases:6.25%
controls:1.26%
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
8
16
120
1255
0
11
128
1260
—
—
—
—
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
7.8e-01
3.7e-01
9.4e-01
—
7.1e-01
8.6e-01
6.3e-01
cases:34.38%
controls:19.35%
cases:15.63%
controls:11.33%
cases:5.47%
controls:2.20%
—
—
cases:4.69%
controls:2.36%
cases:25.40%
controls:12.60%
cases:45.61%
controls:30.97%
44
246
84
1025
20
144
108
1127
7
28
121
1243
—
6
30
122
1241
32
157
94
1089
52
350
62
780
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.9e-01
8.4e-01
—
—
—
1.6e+00
2.4e-01
cases:5.47%
controls:4.56%
cases:7.03%
controls:3.15%
—
—
—
—
—
—
cases:11.11%
controls:2.41%
cases:10.53%
controls:8.50%
7
58
121
1213
9
40
119
1231
—
—
—
14
30
112
1216
12
96
102
1034
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.8e-01
5.2e-01
1.3e+00
—
1.6e+00
6.5e-01
-2.6e-02
cases:13.28%
controls:10.39%
cases:13.28%
controls:8.34%
cases:7.81%
controls:2.36%
—
—
cases:8.59%
controls:1.89%
cases:15.87%
controls:8.99%
cases:23.68%
controls:24.16%
17
132
111
1139
17
106
111
1165
10
30
118
1241
—
11
24
117
1247
20
112
106
1134
27
273
87
857
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.8e-01
4.7e-01
1.1e+00
—
1.6e+00
6.3e-01
3.8e-01
cases:14.06%
controls:10.07%
cases:13.28%
controls:8.73%
cases:5.47%
controls:1.97%
—
—
cases:7.81%
controls:1.73%
cases:15.08%
controls:8.67%
cases:25.44%
controls:18.94%
18
128
110
1143
17
111
111
1160
7
25
121
1246
—
10
22
118
1249
19
108
107
1138
29
214
85
916
Platelets [#/volume] in Blood
26515-7 [3007461]
2.8e-01
4.5e-01
1.2e+00
—
1.6e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.16%
cases:18.75%
controls:12.82%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.91%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
180
105
1091
24
163
104
1108
12
40
116
1231
—
16
37
112
1234
29
165
97
1081
41
355
73
775
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.6e-01
4.5e-01
1.2e+00
—
1.5e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.48%
cases:18.75%
controls:12.82%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.99%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
184
105
1087
24
163
104
1108
12
40
116
1231
—
16
38
112
1233
29
165
97
1081
41
355
73
775
MCH [Entitic mass]
28539-5 [3035941]
2.6e-01
4.5e-01
1.2e+00
—
1.5e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.48%
cases:18.75%
controls:12.82%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.99%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
184
105
1087
24
163
104
1108
12
40
116
1231
—
16
38
112
1233
29
165
97
1081
41
355
73
775
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.6e-01
5.1e-01
1.2e+00
—
1.5e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.40%
cases:19.53%
controls:12.75%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.99%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
183
105
1088
25
162
103
1109
12
40
116
1231
—
16
38
112
1233
29
165
97
1081
41
355
73
775
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.6e-01
4.5e-01
1.2e+00
—
1.5e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.48%
cases:18.75%
controls:12.82%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.99%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
184
105
1087
24
163
104
1108
12
40
116
1231
—
16
38
112
1233
29
165
97
1081
41
355
73
775
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.6e-01
4.5e-01
1.2e+00
—
1.5e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.48%
cases:18.75%
controls:12.82%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.99%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
184
105
1087
24
163
104
1108
12
40
116
1231
—
16
38
112
1233
29
165
97
1081
41
355
73
775
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.6e-01
4.5e-01
1.2e+00
—
1.5e+00
6.7e-01
2.0e-01
cases:17.97%
controls:14.48%
cases:18.75%
controls:12.82%
cases:9.38%
controls:3.15%
—
—
cases:12.50%
controls:2.99%
cases:23.02%
controls:13.24%
cases:35.96%
controls:31.42%
23
184
105
1087
24
163
104
1108
12
40
116
1231
—
16
38
112
1233
29
165
97
1081
41
355
73
775
Senile nuclear cataract
H25.1 [45581628]
1.5e+00
-1.0e+50
—
—
—
-1.0e+50
6.0e-01
cases:7.03%
controls:1.65%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:6.14%
controls:3.45%
9
21
119
1250
0
10
128
1261
—
—
—
0
10
126
1236
7
39
107
1091
Thorax X-ray examination
GD1AA [2001303617]
1.3e+00
9.1e-01
—
—
—
1.1e+00
1.0e+00
cases:10.94%
controls:3.38%
cases:5.47%
controls:2.28%
—
—
—
—
—
—
cases:5.56%
controls:1.85%
cases:14.04%
controls:5.66%
14
43
114
1228
7
29
121
1242
—
—
—
7
23
119
1223
16
64
98
1066
Treatment plan or consultation
WZC00 [2001310885]
9.4e-01
—
—
—
—
—
1.1e+00
cases:5.47%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:4.34%
7
28
121
1243
—
—
—
—
—
14
49
100
1081
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
6.2e-01
—
-1.0e+50
—
—
1.2e+00
1.1e+00
cases:6.25%
controls:3.46%
—
—
cases:0.00%
controls:0.39%
—
—
—
—
cases:5.56%
controls:1.69%
cases:16.67%
controls:6.19%
8
44
120
1227
—
0
5
128
1266
—
—
7
21
119
1225
19
70
95
1060
Laboratory Visit
OMOP4822461 [32036]
1.8e-01
3.7e-01
9.2e-01
—
1.1e+00
4.5e-01
1.6e-01
cases:19.53%
controls:16.92%
cases:22.66%
controls:16.84%
cases:13.28%
controls:5.74%
—
—
cases:14.06%
controls:5.35%
cases:26.19%
controls:18.46%
cases:38.60%
controls:34.78%
25
215
103
1056
29
214
99
1057
17
73
111
1198
—
18
68
110
1203
33
230
93
1016
44
393
70
737
Office Visit
OMOP4822458 [581477]
1.1e+00
4.9e-01
2.1e+00
—
—
1.3e+00
6.9e-01
cases:18.75%
controls:7.40%
cases:3.91%
controls:2.44%
cases:3.91%
controls:0.47%
—
—
—
—
cases:8.73%
controls:2.57%
cases:15.79%
controls:8.58%
24
94
104
1177
5
31
123
1240
5
6
123
1265
—
—
11
32
115
1214
18
97
96
1033
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
—
0
18
126
1228
—
Ménière disease
H81.0 [45567143]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
ethylmorphine; oral
R05DA01 [21603397]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
0
6
128
1265
—
—
—
0
6
126
1240
—
Foreign body in skin
S15 [2002000980]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
hyaluronic acid; parenteral
M09AX01 [21604179]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
114
1123
Orthostatic test
SPAT1101 [2001700202]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
Diabetes mellitus arising in pregnancy
O24.4 [45543922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
11
114
1119
Emergency care or similar visit
WYA10 [2001310872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
lidocaine, combinations
N01BB52 [21604241]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
114
1123
cyproterone and estrogen
G03HB01 [21602617]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
0
7
128
1264
—
—
—
0
5
126
1241
—
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
-8.1e-03
-1.8e-01
—
—
—
-1.3e-01
3.2e-02
cases:12.50%
controls:12.59%
cases:7.03%
controls:8.34%
—
—
—
—
—
—
cases:7.94%
controls:8.91%
cases:14.91%
controls:14.51%
16
160
112
1111
9
106
119
1165
—
—
—
10
111
116
1135
17
164
97
966
Fatty (change of) liver, not elsewhere classified
K76.0 [45601189]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2.8e-01
—
-1.0e+50
—
—
—
2.1e-01
cases:5.47%
controls:4.17%
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:7.02%
controls:5.75%
7
53
121
1218
—
0
6
128
1265
—
—
—
8
65
106
1065
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
6
128
1265
—
—
—
—
—
0
9
114
1121
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:2.12%
—
—
—
—
—
—
5
24
109
1106
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
semaglutide; oral, parenteral
A10BJ06 [1501778]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
-1.0e+50
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.63%
—
—
—
—
cases:0.00%
controls:0.39%
—
—
cases:0.00%
controls:0.71%
0
8
128
1263
0
8
128
1263
—
—
0
5
128
1266
—
0
8
114
1122
Arthropathic psoriasis
L40.5 [45557703]
1.0e+50
1.0e+50
1.0e+50
—
—
—
1.0e+50
cases:11.72%
controls:0.00%
cases:10.16%
controls:0.00%
cases:4.69%
controls:0.00%
—
—
—
—
—
—
cases:19.30%
controls:0.00%
15
0
113
1271
13
0
115
1271
6
0
122
1271
—
—
—
22
0
92
1130
Bacterial pneumonia, unspecified
J15.9 [45557621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
128
1261
—
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
9.8e-01
—
—
—
—
5.2e-01
—
—
cases:4.69%
controls:1.81%
—
—
—
—
—
—
—
—
cases:10.53%
controls:6.55%
—
6
23
122
1248
—
—
—
—
12
74
102
1056
Periodontal treatment
SDA03 [2001310328]
—
—
—
—
—
—
6.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.65%
controls:5.31%
—
—
—
—
—
—
11
60
103
1070
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
12
114
1118
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
0
6
128
1265
—
—
—
—
0
5
114
1125
Other angina pectoris stenosed coronary artery
I20.81 [2000502397]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.79%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
0
10
128
1261
0
5
128
1266
—
—
—
—
0
11
114
1119
Emergency Medicine
93 [38004510]
5.7e-01
2.3e-01
—
—
—
9.8e-01
2.3e-01
cases:9.38%
controls:5.51%
cases:5.47%
controls:4.41%
—
—
—
—
—
—
cases:7.94%
controls:3.13%
cases:11.40%
controls:9.29%
12
70
116
1201
7
56
121
1215
—
—
—
10
39
116
1207
13
105
101
1025
Osteoarthrosis of knee
L90 [2002000709]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
5
128
1266
—
—
—
—
—
0
5
114
1125
norethisterone and ethinylestradiol
G03AA05 [21602478]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.42%
cases:0.00%
controls:0.87%
—
—
—
—
—
—
cases:0.00%
controls:0.88%
cases:0.00%
controls:1.86%
0
18
128
1253
0
11
128
1260
—
—
—
0
11
126
1235
0
21
114
1109
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
4.8e-01
7.5e-01
-1.0e+50
—
—
5.0e-01
3.4e-01
cases:14.84%
controls:9.76%
cases:11.72%
controls:5.90%
cases:0.00%
controls:1.26%
—
—
—
—
cases:9.52%
controls:6.02%
cases:28.07%
controls:21.77%
19
124
109
1147
15
75
113
1196
0
16
128
1255
—
—
12
75
114
1171
32
246
82
884
Puncture of maxillary antrum
TDM10 [2001301819]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
128
1263
—
—
—
—
—
—
cinchocaine
C05AD04 [21601621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
Extraction of multiple teeth
EBA15 [2001301927]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
6
114
1124
dexamethasone
D10AA03 [21602286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
—
Cerebral infarction due to thrombosis of cerebral arteries
I63.3 [45562366]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
5
126
1241
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.1e+00
1.6e+00
—
—
—
—
3.6e-01
cases:6.25%
controls:2.12%
cases:4.69%
controls:1.02%
—
—
—
—
—
—
—
—
cases:4.39%
controls:3.10%
8
27
120
1244
6
13
122
1258
—
—
—
—
5
35
109
1095
Menopausal and female climacteric states
N95.1 [45548683]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
Congestive heart failure
I50.0 [45567179]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
9
114
1121
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.97%
controls:0.40%
—
—
—
—
—
—
—
5
5
121
1241
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
1.7e-01
—
—
—
—
—
4.6e-01
cases:3.91%
controls:3.30%
—
—
—
—
—
—
—
—
—
—
cases:6.14%
controls:3.98%
5
42
123
1229
—
—
—
—
—
7
45
107
1085
Other psoriasis
L40.8 [45567355]
—
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:0.00%
cases:5.26%
controls:0.00%
—
—
—
—
—
9
0
117
1246
6
0
108
1130
Tinea unguium
B35.1 [45590850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
8
114
1122
naproxen; oral, rectal
M01AE02 [21603968]
3.3e-02
—
—
—
—
—
-6.8e-02
cases:8.59%
controls:8.34%
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:8.41%
11
106
117
1165
—
—
—
—
—
9
95
105
1035
Hand and fingers X-ray examination
ND2AA [2001307607]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:0.97%
—
—
—
—
—
—
6
11
108
1119
Transanal ultrasonography
XJH00 [2001305132]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
Type 2 diabetes mellitus, with renal complications
E11.2 [45605400]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
6
114
1124
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
7.8e-01
—
—
—
—
—
5.2e-01
cases:4.69%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:2.65%
6
28
122
1243
—
—
—
—
—
5
30
109
1100
timolol, combinations
S01ED51 [21603705]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.97%
controls:1.04%
—
—
—
—
—
—
—
5
13
121
1233
—
Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture
584-3 [3020321]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
Inguinal hernia
K40 [45543305]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
Otolaryngology
4 [38004449]
1.4e-01
9.9e-01
—
—
—
1.2e+00
7.9e-01
cases:11.72%
controls:10.31%
cases:10.16%
controls:4.01%
—
—
—
—
—
—
cases:7.94%
controls:2.65%
cases:20.18%
controls:10.27%
15
131
113
1140
13
51
115
1220
—
—
—
10
33
116
1213
23
116
91
1014
Internal fixation of fracture of ankle using wire, rod, cerclage or pin
NHJ10 [2001308333]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
0
5
128
1266
—
—
—
0
5
126
1241
—
Excessive and frequent menstruation with regular cycle
N92.0 [45577544]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
8
128
1263
—
—
—
—
—
0
8
114
1122
Psoriasis and similar disorders, Psoriasis pustulosa
69610 [2000304361]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.91%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
123
1271
—
—
—
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
6
114
1124
flecainide; oral, parenteral
C01BC04 [21600266]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
cases:0.00%
controls:0.44%
—
—
—
—
—
0
5
126
1241
0
5
114
1125
risperidone; oral, parenteral
N05AX08 [21604559]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
0
8
128
1263
0
6
128
1265
—
—
—
0
7
126
1239
—
Familial hypercholesterolaemia
E78.00 [2000501513]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
insulin glulisine; parenteral
A10AB06 [21600720]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
5
128
1266
—
—
—
—
—
0
5
114
1125
Hypersensitivity skin testing
268377001 [4147813]
-1.0e+50
—
—
—
—
—
1.5e+00
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.97%
0
8
128
1263
—
—
—
—
—
5
11
109
1119
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.0e+00
—
—
—
—
1.3e+00
3.2e-01
cases:7.03%
controls:2.60%
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.28%
cases:7.89%
controls:5.84%
9
33
119
1238
—
—
—
—
6
16
120
1230
9
66
105
1064
Assistance to normal delivery
MAX99 [2001306918]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
6
128
1265
—
—
—
—
—
0
6
114
1124
Fall on same level involving ice and snow
W00 [45756242]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
8
128
1263
—
—
—
—
—
0
7
114
1123
Outpatient Hospital
22 [8756]
5.8e-01
4.9e-01
1.5e+00
1.0e+50
1.5e+00
5.1e-01
5.6e-01
cases:33.59%
controls:22.03%
cases:10.16%
controls:6.45%
cases:3.91%
controls:0.87%
cases:7.03%
controls:0.00%
cases:4.69%
controls:1.10%
cases:11.11%
controls:6.98%
cases:30.70%
controls:20.27%
43
280
85
991
13
82
115
1189
5
11
123
1260
9
0
119
1271
6
14
122
1257
14
87
112
1159
35
229
79
901
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
—
—
—
—
—
—
3.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:5.75%
—
—
—
—
—
—
9
65
105
1065
Sinusitis acute/chronic
R75 [2002000943]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
hypromellose
S01KA02 [21605115]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:1.50%
—
—
—
—
—
—
5
17
109
1113
Alcoholic cirrhosis of liver
K70.3 [45596343]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
Opening and preparing the root canals, extremely complicated And time consuming
SGA05 [2001310383]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
8
128
1263
—
—
—
—
—
0
6
114
1124
Psoriasis
L40 [45577035]
1.0e+50
—
—
—
—
1.0e+50
—
cases:3.91%
controls:0.00%
—
—
—
—
—
—
—
—
cases:7.94%
controls:0.00%
—
—
5
0
123
1271
—
—
—
—
10
0
116
1246
—
Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay
44448-9 [3044355]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
furosemide; oral, parenteral
C03CA01 [21601518]
5.4e-01
4.3e-01
—
—
—
7.9e-01
7.8e-01
cases:7.81%
controls:4.72%
cases:6.25%
controls:4.17%
—
—
—
—
—
—
cases:9.52%
controls:4.57%
cases:12.28%
controls:6.02%
10
60
118
1211
8
53
120
1218
—
—
—
12
57
114
1189
14
68
100
1062
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.14%
controls:1.86%
—
—
—
—
—
—
7
21
107
1109
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
3.2e-01
—
—
—
—
8.9e-01
9.6e-01
cases:5.47%
controls:4.01%
—
—
—
—
—
—
—
—
cases:4.76%
controls:2.01%
cases:8.77%
controls:3.54%
7
51
121
1220
—
—
—
—
6
25
120
1221
10
40
104
1090
Extensive endovascular dilatation of coronary (PTCA) arteries
FN1BT [2001303063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
—
-1.0e+50
—
—
—
—
1.5e+00
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.97%
—
0
6
128
1265
—
—
—
—
5
11
109
1119
Intramural leiomyoma of uterus
D25.1 [45547585]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
5
128
1266
—
—
—
—
—
0
6
114
1124
quetiapine; oral
N05AH04 [21604544]
—
—
—
—
—
1.2e+00
4.9e-01
—
—
—
—
—
—
—
—
—
—
cases:3.97%
controls:1.28%
cases:4.39%
controls:2.74%
—
—
—
—
—
5
16
121
1230
5
31
109
1099
trazodone; oral
N06AX05 [21604734]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
General health counselling
SPAT1312 [2001700413]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:4.87%
—
—
—
—
—
—
9
55
105
1075
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
—
—
—
—
—
9.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:1.68%
—
—
—
—
—
—
5
19
109
1111
Breast cancer
115 [2001600115]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
114
1123
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
7
126
1239
—
Angiography of the heart and coronary arteries
81 [2002100125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
128
1262
—
—
—
—
—
—
Dilated cardiomyopathy
I42.0 [45586581]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
9
114
1121
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
—
1.9e+00
—
—
—
—
—
—
—
cases:4.69%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
6
9
122
1262
—
—
—
—
—
Acute sinusitis, unspecified
J01.9 [45543252]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
calcium carbonate; oral
A12AA04 [21600863]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
formoterol; inhalant
R03AC13 [21603267]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
5
126
1241
—
Glucose [Moles/volume] in Serum or Plasma --2 hours post dose glucose
14759-5 [3016701]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
2.5e-01
1.1e+00
—
—
—
1.3e+00
1.0e+00
cases:3.91%
controls:3.07%
cases:4.69%
controls:1.57%
—
—
—
—
—
—
cases:5.56%
controls:1.52%
cases:8.77%
controls:3.27%
5
39
123
1232
6
20
122
1251
—
—
—
7
19
119
1227
10
37
104
1093
Screening of depression or other psychiatric problem
SPAT1246 [2001700347]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
9.6e-01
1.3e+00
—
—
—
1.4e+00
7.6e-01
cases:8.59%
controls:3.46%
cases:6.25%
controls:1.81%
—
—
—
—
—
—
cases:7.14%
controls:1.93%
cases:9.65%
controls:4.78%
11
44
117
1227
8
23
120
1248
—
—
—
9
24
117
1222
11
54
103
1076
Ventricular premature depolarization
I49.3 [45538386]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
5
128
1266
—
—
—
—
—
0
6
114
1124
Ankle symptom/complaint
L16 [2002000640]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
0
10
128
1261
—
—
—
—
0
8
126
1238
—
carbamide
D02AE01 [21601975]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.62%
—
—
—
—
—
—
5
7
109
1123
Postpartum check-up
SPAT1380 [2001700480]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
6
128
1265
—
—
—
—
—
0
5
114
1125
Other primary gonarthrosis
M17.1 [45596493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
Teeth/gum disease
D82 [2002000380]
5.2e-01
—
—
—
—
—
8.2e-02
cases:4.69%
controls:2.83%
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:4.87%
6
36
122
1235
—
—
—
—
—
6
55
108
1075
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
1.0e+00
—
—
—
—
—
5.8e-01
cases:6.25%
controls:2.28%
—
—
—
—
—
—
—
—
—
—
cases:9.65%
controls:5.66%
8
29
120
1242
—
—
—
—
—
11
64
103
1066
Extended examination of mouth
SAA03 [2001310276]
8.7e-01
-1.0e+50
—
—
—
—
2.0e-01
cases:5.47%
controls:2.36%
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
cases:7.02%
controls:5.84%
7
30
121
1241
0
20
128
1251
—
—
—
—
8
66
106
1064
Other and unspecified convulsions
R56.8 [45602033]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum
17791-5 [3027450]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
114
1123
Implementation of podiatry rehabilitation plan
SPAT1225 [2001700326]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
lovastatin; oral
C10AA02 [21601857]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.26%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
0
16
128
1255
0
7
128
1264
—
—
—
0
10
126
1236
—
Assessment of need for aid
SPAT1229 [2001700330]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
Other specified intervertebral disc degeneration
M51.3 [45591865]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
12
128
1259
—
—
—
—
—
0
7
114
1123
dexamethasone
S02BA06 [21605168]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
—
Submucous leiomyoma of uterus
D25.0 [45542691]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
terbutaline; inhalant
R03AC03 [21603257]
2.8e-01
-1.0e+50
-1.0e+50
—
—
—
4.5e-01
cases:3.91%
controls:2.99%
cases:0.00%
controls:1.73%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:4.39%
controls:2.83%
5
38
123
1233
0
22
128
1249
0
6
128
1265
—
—
—
5
32
109
1098
temazepam; oral
N05CD07 [21604642]
5.5e-01
—
-1.0e+50
—
-1.0e+50
—
4.7e-01
cases:5.47%
controls:3.23%
—
—
cases:0.00%
controls:0.63%
—
—
cases:0.00%
controls:0.71%
—
—
cases:5.26%
controls:3.36%
7
41
121
1230
—
0
8
128
1263
—
0
9
128
1262
—
6
38
108
1092
Benign neoplasm: Skin of other and unspecified parts of face
D23.3 [45595740]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
128
1263
—
—
—
—
—
—
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
5.0e-01
—
—
—
—
—
1.1e+00
cases:5.47%
controls:3.38%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:3.19%
7
43
121
1228
—
—
—
—
—
10
36
104
1094
No procedures
SPAT1301 [2001700402]
8.2e-01
—
—
—
—
—
—
cases:4.69%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
6
27
122
1244
—
—
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
3.2e-01
1.7e-01
—
—
—
3.9e-01
7.1e-01
cases:22.66%
controls:17.55%
cases:8.59%
controls:7.32%
—
—
—
—
—
—
cases:7.94%
controls:5.54%
cases:28.95%
controls:16.73%
29
223
99
1048
11
93
117
1178
—
—
—
10
69
116
1177
33
189
81
941
Car occupant [any] injured in unspecified traffic accident
V49.9 [45566025]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
6
128
1265
—
—
—
—
—
0
5
114
1125
Tissue Pathology biopsy report
66121-5 [40768804]
7.2e-01
—
—
—
—
—
5.3e-01
cases:6.25%
controls:3.15%
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:4.78%
8
40
120
1231
—
—
—
—
—
9
54
105
1076
tacrolimus
D11AH01 [21602338]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.80%
—
—
—
—
—
—
5
9
109
1121
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
128
1263
—
—
—
—
—
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
3.6e-01
—
—
—
—
9.8e-01
3.0e-01
cases:4.69%
controls:3.30%
—
—
—
—
—
—
—
—
cases:3.97%
controls:1.52%
cases:6.14%
controls:4.60%
6
42
122
1229
—
—
—
—
5
19
121
1227
7
52
107
1078
Monitored bed care
WX892 [2001310850]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
8
128
1263
0
6
128
1265
—
—
—
—
—
tretinoin, combinations; ointment
D10AD51 [21602298]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.94%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
12
128
1259
0
5
128
1266
—
—
—
0
9
126
1237
—
Lyme disease
A69.2 [45595594]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
1.3e+00
—
—
—
—
—
1.5e+00
cases:3.91%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:1.06%
5
14
123
1257
—
—
—
—
—
5
12
109
1118
Paraesthesia of skin
R20.2 [45568120]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
8
128
1263
—
—
—
—
—
0
6
114
1124
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
6.4e-01
—
—
—
—
1.4e+00
3.2e-01
cases:4.69%
controls:2.52%
—
—
—
—
—
—
—
—
cases:3.97%
controls:1.04%
cases:5.26%
controls:3.89%
6
32
122
1239
—
—
—
—
5
13
121
1233
6
44
108
1086
Exposure to other specified factors
X58 [45756411]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.77%
0
10
128
1261
—
—
—
—
—
0
20
114
1110
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
cases:4.39%
controls:1.50%
—
—
—
—
—
0
5
126
1241
5
17
109
1113
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
—
—
—
—
—
-2.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:6.81%
—
—
—
—
—
—
6
77
108
1053
lisinopril and diuretics
C09BA03 [21601805]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
cases:0.00%
controls:0.53%
0
5
128
1266
0
5
128
1266
—
—
—
0
5
126
1241
0
6
114
1124
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
—
—
—
—
—
7.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:2.21%
—
—
—
—
—
—
5
25
109
1105
pH of Specimen
17433-4 [3019225]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
—
Postmenopausal bleeding
N95.0 [45567872]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
11
114
1119
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
11
114
1119
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.62%
—
—
—
—
—
—
5
7
109
1123
Nursing episode
950 [44777714]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
0
6
128
1265
—
—
—
—
—
Cardiac arrhythmia, unspecified
I49.9 [45581778]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
Hypertension uncomplicated
K86 [2002000613]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
0
8
128
1263
0
5
128
1266
—
—
—
—
—
ibuprofen
R02AX02 [1588667]
3.4e-01
7.1e-01
—
—
1.2e+00
7.1e-01
1.3e-01
cases:37.50%
controls:29.98%
cases:23.44%
controls:13.06%
—
—
—
—
cases:6.25%
controls:1.89%
cases:21.43%
controls:11.80%
cases:35.09%
controls:32.21%
48
381
80
890
30
166
98
1105
—
—
8
24
120
1247
27
147
99
1099
40
364
74
766
Extensive global examination
SPAT1360 [2001700461]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
—
colestyramine; oral
C10AC01 [21601876]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
5
128
1266
—
—
—
—
—
0
9
114
1121
escitalopram; oral
N06AB10 [21604718]
3.7e-01
—
—
—
—
—
2.8e-01
cases:5.47%
controls:3.86%
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:3.36%
7
49
121
1222
—
—
—
—
—
5
38
109
1092
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
6.3e-01
-1.0e+50
—
—
—
—
6.8e-01
cases:3.91%
controls:2.12%
cases:0.00%
controls:1.34%
—
—
—
—
—
—
—
—
cases:5.26%
controls:2.74%
5
27
123
1244
0
17
128
1254
—
—
—
—
6
31
108
1099
Sampling
SPAT1263 [2001700364]
—
—
—
—
—
—
-1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.14%
controls:6.81%
—
—
—
—
—
—
7
77
107
1053
Pulpitis
K04.0 [45591570]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
fluoxetine; oral
N06AB03 [21604711]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.87%
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:1.04%
cases:0.00%
controls:1.42%
—
0
11
128
1260
—
—
0
5
128
1266
0
13
126
1233
0
16
114
1114
Curettage of cervix and body of uterus
LCA13 [2001306553]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
0
6
128
1265
—
—
—
—
—
0
11
114
1119
lercanidipine; oral
C08CA13 [21601759]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
0
8
128
1263
—
—
0
21
126
1225
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
0
5
128
1266
—
—
—
0
5
126
1241
—
Lump/swelling localized
S04 [2002000969]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
10
114
1120
Routine general health check-up of other defined subpopulations
Z10.8 [45609907]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
128
1266
—
—
—
—
—
—
Dental examination
Z01.2 [45581002]
—
—
—
—
—
—
-2.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:6.90%
—
—
—
—
—
—
6
78
108
1052
Epilepsy
G40 [45595935]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
114
1125
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
Retention of urine
R33 [45587507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
8
114
1122
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
6
114
1124
omeprazole; oral, parenteral
A02BC01 [21600096]
4.7e-01
—
—
—
—
—
2.0e-01
cases:6.25%
controls:4.01%
—
—
—
—
—
—
—
—
—
—
cases:5.26%
controls:4.34%
8
51
120
1220
—
—
—
—
—
6
49
108
1081
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
4.9e-01
3.8e-01
—
—
5.2e-01
4.5e-01
4.9e-01
cases:10.16%
controls:6.45%
cases:9.38%
controls:6.61%
—
—
—
—
cases:3.91%
controls:2.36%
cases:11.11%
controls:7.38%
cases:14.91%
controls:9.73%
13
82
115
1189
12
84
116
1187
—
—
5
30
123
1241
14
92
112
1154
17
110
97
1020
telithromycin; oral
J01FA15 [21602983]
1.2e+00
—
—
—
—
—
—
cases:3.91%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
123
1255
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
-1.0e+50
—
—
—
—
4.5e-01
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
cases:4.39%
controls:2.83%
—
0
11
128
1260
—
—
—
—
5
32
109
1098
Polyuria
R35 [45539331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
114
1123
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
5
128
1266
—
—
—
—
—
0
9
114
1121
Benign paroxysmal vertigo
H81.1 [45572061]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
9
114
1121
Preventive oral health care, short
SCA01 [2001310302]
—
—
—
—
—
—
2.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:3.63%
—
—
—
—
—
—
5
41
109
1089
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
128
1263
—
—
—
—
—
—
metformin; oral
A10BA02 [21600747]
3.8e-01
3.6e-01
—
—
9.8e-01
4.8e-01
6.9e-01
cases:10.16%
controls:7.16%
cases:8.59%
controls:6.14%
—
—
—
—
cases:3.91%
controls:1.49%
cases:10.32%
controls:6.66%
cases:17.54%
controls:9.65%
13
91
115
1180
11
78
117
1193
—
—
5
19
123
1252
13
83
113
1163
20
109
94
1021
telmisartan and diuretics
C09DA07 [21601839]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.71%
0
6
128
1265
0
5
128
1266
—
—
—
0
6
126
1240
0
8
114
1122
Dizziness and giddiness
R42 [45568132]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
0
14
126
1232
—
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
8
114
1122
pivmecillinam; oral
J01CA08 [21602827]
7.1e-02
—
—
—
—
—
-1.1e-01
cases:7.81%
controls:7.32%
—
—
—
—
—
—
—
—
—
—
cases:7.02%
controls:7.79%
10
93
118
1178
—
—
—
—
—
8
88
106
1042
dexamethasone
C05AA09 [21601613]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
128
1264
—
—
—
—
—
—
Psoriasis and similar disorders, Other psoriasis[PSORIASIS PUSTULARIS]
6961B [2000405519]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.00%
—
—
—
—
—
—
—
—
—
8
0
120
1271
—
—
—
Psoriasis vulgaris
L40.0 [45543370]
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
cases:22.66%
controls:0.00%
cases:25.00%
controls:0.00%
cases:13.28%
controls:0.00%
cases:6.25%
controls:0.00%
cases:19.53%
controls:0.00%
cases:41.27%
controls:0.00%
—
—
29
0
99
1271
32
0
96
1271
17
0
111
1271
8
0
120
1271
25
0
103
1271
52
0
74
1246
—
Feeling ill
A05 [2002000146]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
9
114
1121
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
128
1265
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
49
153
4.44
14.66
1.4
1.3
465.45
607.00
titre
0.21
11
40
84
401
3.86
13.43
16.5
7.1
—
—
—
0
0
102
634
3.44
9.31
20.1
7.2
0.20
0.19
e9/l
0.52
97
554
94
562
3.18
9.08
19.7
6.9
58.69
57.69
%
0.38
94
536
21
49
4.89
8.76
1.8
1.2
—
—
—
0
0
25
86
3.34
6.12
1.2
1.5
—
—
—
0
0
26
97
3.08
5.56
7.1
4.8
0.25
0.50
%
—
8
35
32
135
2.79
5.50
2.1
1.8
—
—
—
0
0
26
99
3.01
5.36
7.6
4.8
0.13
0.17
%
—
8
35
26
106
2.80
4.73
7.6
4.7
0.50
0.81
%
—
8
43
13
27
5.21
4.63
1.8
1.7
16100.25
16485.00
e6/l
—
8
19
41
211
2.35
4.63
1.3
1.8
—
—
—
0
0
36
175
2.44
4.61
1.3
1.5
—
—
—
0
0
37
187
2.34
4.32
1.3
1.3
1.40
8.52
u/ml
—
6
66
73
486
2.08
4.25
7.3
4.4
82.40
63.22
e6/l
0.12
50
348
92
669
2.16
4.23
6.2
4.2
0.00
10.75
estimate
0.50
21
151
31
146
2.45
4.22
1.2
1.6
—
—
—
0
0
25
106
2.66
4.21
8.5
5.0
0.00
0.31
%
—
5
36
91
662
2.13
4.14
6.2
4.1
0.00
0.00
estimate
-0.00
21
145
86
615
2.08
4.06
9.5
8.2
1.21
1.21
mmol/l
0.29
76
530
10
18
5.90
4.06
1.5
1.6
—
—
—
0
0
30
143
2.41
3.97
1.4
1.4
—
—
—
0
0
76
524
2.02
3.92
5.3
3.9
6.01
6.21
ph
0.93
40
300
10
20
5.31
3.77
1.5
1.4
—
—
—
0
0
51
310
2.03
3.69
3.0
2.1
3.29
2.87
mg/l
0.42
43
266
91
678
2.03
3.68
6.2
4.2
0.00
0.00
estimate
-0.00
19
137
61
396
1.98
3.67
4.4
4.0
13.43
7.55
mg/mmol
0.45
42
255
48
289
2.02
3.55
6.5
4.0
—
0.00
—
0
5
61
412
1.87
3.15
3.6
3.3
7.72
7.70
mmol/l
0.01
54
351
44
268
1.95
3.09
9.4
5.4
—
—
—
0
0
37
212
2.02
3.09
1.5
1.3
28.09
28.13
iu/ml
—
10
71
27
141
2.14
2.86
6.7
7.6
7.40
7.42
ph
0.40
16
87
57
387
1.81
2.83
15.1
7.3
—
—
—
0
0
41
254
1.88
2.70
1.5
1.4
3.18
2.39
g/l
0.79
24
142
22
110
2.19
2.59
2.9
3.5
65.35
73.52
e9/l
0.55
15
79
56
387
1.76
2.57
3.7
3.3
81.71
47.66
mg/l
0.35
38
255
53
364
1.75
2.47
3.9
3.4
—
—
—
0
0
111
941
1.98
2.46
15.4
8.7
76.84
81.06
u/l
0.61
106
886
15
65
2.47
2.41
1.9
2.6
—
—
—
0
0
76
580
1.70
2.39
15.3
12.9
1.17
1.24
inr
0.62
65
492
60
436
1.67
2.23
5.8
3.7
16.97
52.13
e6/l
1.62
48
337
70
531
1.66
2.19
2.7
2.1
87.13
94.42
pmol/l
0.74
47
279
51
357
1.69
2.17
5.4
3.4
—
0.00
—
0
6
53
375
1.68
2.16
5.5
3.5
0.72
0.31
e6/l
0.29
41
279
23
127
1.98
2.10
3.1
2.0
0.00
0.00
estimate
—
6
29
43
290
1.71
2.09
5.8
4.4
1.02
1.02
kg/l
1.07
33
190
53
379
1.65
2.06
5.4
4.1
7.40
7.40
ph
0.17
39
273
5
11
4.67
1.96
2.0
5.2
309.60
449.00
mg
—
5
11
40
277
1.63
1.73
1.5
1.2
13.00
1.40
u/ml
—
10
60
49
359
1.57
1.67
6.2
4.8
—
—
—
0
0
15
77
2.07
1.67
3.1
3.7
—
—
—
0
0
51
379
1.55
1.63
5.5
4.0
0.00
0.00
estimate
-0.00
20
135
6
20
3.09
1.60
3.7
2.1
4.32
4.24
e9/l
—
6
20
5
15
3.42
1.53
1.4
4.2
—
—
—
0
0
13
66
2.07
1.49
2.1
2.1
0.00
0.00
estimate
—
5
22
7
28
2.58
1.47
1.1
3.2
9.20
9.40
pmol/l
—
7
28
62
493
1.47
1.40
2.4
2.0
—
—
—
0
0
42
310
1.51
1.36
2.2
2.3
1.79
1.59
mg/l
0.12
33
255
19
116
1.74
1.30
8.7
8.7
—
—
—
0
0
27
183
1.59
1.26
2.1
2.1
—
—
—
0
0
61
494
1.43
1.21
2.3
2.1
1.39
1.34
mmol/l
0.31
51
403
8
38
2.17
1.20
1.1
1.4
—
—
—
0
0
20
128
1.66
1.16
1.4
1.5
—
—
—
0
0
8
40
2.06
1.14
1.1
1.4
—
—
—
0
0
8
40
2.06
1.14
1.1
1.4
—
—
—
0
0
62
509
1.40
1.12
5.8
4.1
0.00
0.00
estimate
-0.00
17
116
29
206
1.52
1.11
5.0
3.5
1.43
1.61
e6/l
0.08
15
108
8
41
2.01
1.11
1.1
1.4
—
—
—
0
0
8
41
2.01
1.11
1.1
1.4
—
—
—
0
0
9
45
2.07
1.07
1.6
1.2
—
—
—
0
0
16
99
1.70
1.05
1.3
1.1
—
—
—
0
0
21
140
1.59
1.05
3.0
4.7
7.37
7.39
ph
0.50
14
86
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
33
248
1.44
0.96
5.5
3.6
902.76
103.91
ng/l
0.49
25
196
20
135
1.56
0.96
1.7
1.3
—
—
—
0
0
122
1145
1.64
0.94
34.3
17.7
19.50
23.53
mg/l
1.23
112
964
6
31
1.98
0.85
3.8
1.9
57.67
57.77
%
—
6
31
6
31
1.98
0.85
1.7
1.1
—
—
—
0
0
47
383
1.35
0.85
4.4
3.7
0.00
0.00
estimate
-0.00
17
110
22
158
1.47
0.81
3.5
2.3
262.78
137.42
ug/g
0.77
22
130
15
99
1.58
0.79
4.9
3.5
—
—
—
0
0
10
60
1.72
0.74
21.5
6.4
—
—
—
0
0
13
86
1.57
0.69
3.7
3.3
—
—
—
0
0
5
28
1.81
0.67
3.0
3.0
—
—
—
0
0
6
101
0.58
0.65
5.2
2.7
5.25
6.23
ug/l
—
6
89
8
50
1.64
0.62
1.4
2.8
—
—
—
0
0
118
1120
1.40
0.62
5.8
5.3
6.06
5.92
mmol/l
0.50
112
1030
0
20
0.00
0.61
0.0
3.0
—
2.97
—
0
20
10
64
1.61
0.60
1.2
1.1
—
—
—
0
0
8
121
0.64
0.58
1.4
1.5
—
—
—
0
0
6
37
1.65
0.56
1.3
1.4
0.27
0.24
g/l
—
6
37
6
37
1.65
0.56
1.3
1.4
1.17
1.11
g/l
—
6
37
9
59
1.56
0.56
2.0
1.9
—
—
—
0
0
114
1085
1.31
0.51
5.6
4.3
1.35
1.27
mmol/l
0.78
109
998
22
174
1.32
0.49
1.4
1.3
—
—
—
0
0
7
49
1.45
0.46
2.3
5.7
1.73
1.50
mg/l
—
7
42
29
241
1.26
0.45
1.8
1.9
416.74
454.55
pmol/l
0.29
23
202
8
57
1.43
0.43
4.9
3.5
36.98
36.92
°c
—
8
57
112
1071
1.26
0.42
6.0
5.4
2.10
1.93
mu/l
0.60
107
978
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
117
1125
1.29
0.41
6.1
5.2
1.41
1.46
mmol/l
0.71
112
1039
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
12
92
1.33
0.33
5.3
3.7
—
—
—
0
0
95
903
1.17
0.33
5.2
4.4
14.82
14.88
pmol/l
0.07
90
812
117
1132
1.24
0.32
6.8
5.3
4.46
4.61
mmol/l
0.81
112
1053
10
129
0.76
0.29
3.8
2.8
33.80
31.81
u/l
—
10
103
113
1093
1.20
0.29
8.4
6.6
41.17
39.61
mmol/mol
1.07
107
1033
119
1158
1.22
0.27
7.1
6.0
2.65
2.70
mmol/l
0.19
114
1074
60
562
1.12
0.23
4.9
3.0
—
—
estimate
—
0
0
5
41
1.23
0.22
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
211.55
—
0
11
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
1.77
—
0
8
0
14
0.00
0.20
0.0
1.1
—
4.14
—
0
8
14
118
1.21
0.20
3.2
2.7
0.23
0.21
g/l
0.19
14
111
7
62
1.14
0.17
1.3
1.2
—
—
—
0
0
11
94
1.19
0.13
1.3
1.5
—
—
—
0
0
22
241
0.90
0.13
2.7
3.2
0.65
0.82
ug/l
0.57
13
156
38
403
0.92
0.12
6.1
5.7
1.88
2.26
ug/l
0.29
33
353
48
500
0.94
0.09
5.9
4.3
27.46
38.49
ng/l
0.59
39
366
16
146
1.11
0.08
8.2
4.6
3.46
39.08
ug/l
0.63
16
117
8
74
1.09
0.07
1.3
3.6
4.50
4.56
pmol/l
—
8
67
8
75
1.07
0.07
2.9
3.0
0.60
0.59
%
—
8
75
8
77
1.04
0.07
2.9
3.0
1.25
1.25
%
—
8
77
125
1238
1.12
0.07
50.1
26.2
91.92
91.21
fl
1.01
125
1229
17
158
1.09
0.06
1.4
1.3
—
—
—
0
0
12
109
1.11
0.06
4.5
2.4
6.07
6.07
ph
—
7
66
125
1239
1.11
0.06
50.8
26.4
132.26
134.65
g/l
0.93
125
1230
125
1239
1.11
0.06
50.1
26.1
30.26
30.34
pg
0.20
125
1230
125
1239
1.11
0.06
51.1
26.5
40.15
40.22
%
0.06
125
1230
12
110
1.10
0.05
1.8
1.3
—
—
—
0
0
38
390
0.96
0.03
4.7
2.7
—
—
—
0
0
122
1214
1.05
0.00
42.8
22.2
79.45
78.12
umol/l
0.12
122
1204
32
326
0.98
0.00
1.3
1.4
—
—
—
0
0
47
464
1.02
0.00
3.6
3.4
—
—
—
0
0
43
432
0.99
0.00
4.5
4.0
—
—
—
0
0
119
1188
1.01
0.00
26.7
15.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
3.75
—
0
8
0
6
0.00
0.00
0.0
3.5
—
1.63
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
77
0.90
-0.00
1.4
1.3
—
—
—
0
0
5
53
0.94
-0.00
3.6
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
57.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
132.60
—
0
5
6
62
0.97
-0.00
5.5
3.4
24.15
711.29
u/ml
—
6
51
0
5
0.00
-0.00
0.0
2.0
—
244.16
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
8.91
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
11.76
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
48.40
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint L12_PSORI_PUSTGEN and mortality.

Females

Parameter HR [95% CI] p-value
L12_PSORI_PUSTGEN 2.109 [1.55, 2.87] < 0.001
Birth year 0.988 [0.98, 1.0] 0.011

During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 289 females with L12_PSORI_PUSTGEN died.

Males

Parameter HR [95% CI] p-value
L12_PSORI_PUSTGEN 2.046 [1.29, 3.24] 0.002
Birth year 0.988 [0.98, 1.0] 0.01

During the follow-up period (1.1.1998 — 31.12.2019), 89 out of 268 males with L12_PSORI_PUSTGEN died.

Mortality risk

Mortality risk for people of age

years, who have L12_PSORI_PUSTGEN.

N-year risk Females Males
1 0.185% 0.352%
5 0.897% 2.262%
10 2.342% 5.795%
15 4.631% 11.36%
20 8.298% 18.627%

Relationships between endpoints

↥

Index endpoint: L12_PSORI_PUSTGEN – Generalized pustular psoriasis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data